The cost of hospital care and pharmaceuticals 2009 - 2012 for patients with rheumatoid arthritis in Norway. by Eriksen, Andreas
The cost of hospital care and 
pharmaceuticals 2009 – 2012 for patients 
with rheumatoid arthritis in Norway. 
 
Andreas Eriksen 
 
 
 
 
 
 
 
 
 
 
Master Thesis 
 
Department of Health Management and Health economics at the 
faculty of medicine 
 
Thesis submitted as a part of the Master of Philosophy Degree in Health Economics, 
Policy and Management 
 
 
UNIVERSITY OF OSLO 
May 2014
II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Andreas Eriksen 
2014 
The cost of hospital care and pharmaceuticals 2009 – 2012 for patients with 
rheumatoid arthritis in Norway. 
Andreas Eriksen 
http://www.duo.uio.no/ 
Publishing: Reprosentralen, Blindern, University of Oslo. 
 
IV 
 
ACKNOWLEDGEMENTS 
First and foremost, I would like to express my gratitude to my supervisor Ivar Sønbø 
Kristiansen for outstanding support and guidance throughout the process of writing 
this thesis. I would also like to thank Maria Kvamme who provided valuable insight 
and support during this project. 
 
I would also like to thank Leena Kiviluoto for educating us on the DRG-system and 
Øyvind Thormodsæter for proofreading. 
 
A special thanks also to Tore Kristian Kvien, Therese Bjor Rønningen and the rest of 
the staff at the Rheumatology out-patient clinic at Diakonhjemmet Sykehus for 
welcoming me to their institution and allowing me to observe and learn about the 
processes in rheumatoid arthritis-treatment. 
 
I would also like to express my gratitude to Steinar Bustad and UCB Norge that 
offered to fund the data collection. In the end the Norwegian Patient Registry 
provided the data free of charge. 
 
 
 
 
 
 
 
 
 
 
 
Andreas Eriksen 
Oslo, May 2014 
 
 
V 
 
SUMMARY 
Rheumatoid arthritis is an inflammatory disease that affect 0.5% - 1.0% of the 
population world-wide and approximately 0.5% in Norway. RA places a considerable 
burden on patients in terms morbidity and mortality, and on society in terms of costs.  
The aim of this master thesis was to explore the costs of hospital care and 
pharmaceuticals in patients with rheumatoid arthritis and study the differences in 
these costs across time and region. 
Data on all episodes of hospital care during 2009 – 2012 were collected from 
the Norwegian Patient Registry using «M05 – Seropositive rheumatoid Arthritis» and 
«M06 – Other Rheumatoid Arthritis» as either main or secondary diagnoses as 
inclusion criteria. The data included information about age-group, sex, region, 
diagnosis and use of biologic pharmaceuticals. Data on pharmaceuticals dispensed 
from pharmacies during 2009 – 2012 were extracted from the Norwegian Prescription 
Database. 
The estimated total costs of hospital care and pharmaceuticals for rheumatoid 
arthritis in Norway were NOK1 billion in 2012. Hospital care and biologic DMARDs 
administered in hospital accounted for 58%, private specialist care 0.6%, 
rehabilitation in private clinics 1.0% and prescription drugs 40% of the costs. The 
registered hospital care costs increased during 2009-2011 and decreased by 5% from 
2011 to 2012. Per capita hospital care costs varied considerably with a difference of 
more than 20% between the regional health authority with the lowest and the highest 
costs. The costs of private specialist care were considerably higher in the South-
Eastern- and the Western Norway regional health authority compared to the Northern- 
and the Central Norway regional health authority in terms of total costs and costs per 
capita. The costs of care in private rehabilitation clinics decreased during the period 
and differed across regions. The Northern Norway regional health authority had the 
highest- and the Western Norway regional health authority had the lowest costs of 
care in private rehabilitation clinics. The costs of patient-administered disease 
modifying antirheumatic drugs (DMARDs) (Biologic and non-biologic) increased 
from NOK351 million to NOK414 million during the period. Despite the increasing 
use of DMARDs there was no reduction in rheumatic surgery.  
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1. Background 
 
 
1.1 Pathology 
Rheumatoid arthritis (RA) is an inflammatory disease that causes pain, swelling, 
stiffness and loss of function in the joints. It occurs when the immune system, which 
normally defends the body from invading organisms, turns its attack against the 
membrane lining the joints. (1) It is an autoimmune disorder causing symmetrical 
polyarthritis of large and small joints, typically presenting between the ages 
of 30 and 50 years (2) Figure 1 illustrates a healthy joint and a joint that is affected by 
RA.  
 
 
FIGURE 1 Illustration of a normal joint and a joint affected by RA 
 
Source: NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases 
 
 
It is not known what triggers the onset of RA. Many have tried to identify factors that 
increase the probability of developing of the disease. Genetics (3), environmental 
factors and infectious agents (4, 5) have all been suggested as possible risk factors. 
Moreover, several lifestyle features are seen among RA-patients, and of the most 
important is smoking status. Di Guiseppe and co-workers (6) conclude that smoking 
is positively associated with Rheumatoid arthritis in their meta-analysis of studies on 
smoking and RA. 
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1.2 HRQOL in rheumatoid arthritis 
Quality of life (QoL) is the perceived level of happiness or gratification in life, or the 
individual`s perception of its situation within a given system of culture and values. 
Rheumatoid arthritis is among the main conditions where QoL is decreased (7). 
Health related quality of life (HRQoL) is an assessment of the effect a disease, 
disorder or disability has on a person’s well-being. The severely debilitating nature of 
rheumatoid arthritis causes challenges in the day to day life of people who develop the 
disease. RA leads to physical activity limitation, disability and premature death. 
Patients with RA who have significant functional disability have three times higher 
risk of mortality compared to the general population (8). Other complications 
associated with the disease are reduced social functioning and a worsening of mental 
health. Health related quality of life in patients with RA is often affected by disability, 
pain, fatigue, depression and comorbidities (9). Rheumatoid arthritis is usually viewed 
as having substantial effect on all aspects of HRQoL (10). Ovayolu and co-workers 
(11) found that RA has a negative impact on HRQoL and that RA-patients scored 
lower than healthy individuals on both the mental - and the physical component.  
 
 
1.3 Epidemiology 
Rheumatoid arthritis affects 0.5% - 1.0% of the population in developed countries 
(12), and approximately 0.5% in Norway (13). The illness is three times more 
frequent in women than men and prevalence increases with age. Incidence ranges 
from 5 to 50 per 100 000 in the adult population in developed countries (12), and 
approximately 25 per 100,000 in Norway (14, 15). Several studies show a decline in 
RA incidence the last decades (16-18). Figure 2 shows the global burden of 
rheumatoid arthritis. The figure is based on data from WHO`s DALY estimates from 
2004. 
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FIGURE 2 Age-standardized disability-adjusted life year (DALY) rates from 
Rheumatoid arthritis by country (per 100,000 inhabitants) 2004.  
 
Source: Vector map from BlankMap-World6, compact.svg by Canuckguy et al., Data from Death and DALY estimates for 2004 
by cause for WHO Member States (Persons, all ages) (2009-11-12). WHO 
URL: http://commons.wikimedia.org/wiki/File:Rheumatoid_arthritis_world_map_-_DALY_-_WHO2004.sv 
 
 
The main causes of death among rheumatoid arthritis-patients are increased incidence 
of cardiovascular disease, respiratory diseases, cancer and infections (19-22). Dadoun 
and co-workers (23) performed a systematic review of studies on mortality in RA the 
last fifty years and found that mortality has decreased among RA-patients, but 
remains higher than for the general population. The review revealed a decrease in the 
incidence mortality rate
1
 (IMR) from 4.7/100 patient-years before 1970 to 2/100 
patient-years after 1983. IMR is here a measure of the mortality among the RA 
population. Mean IMR was measured at 2.7/100 patient-years. They did not, however, 
find a significant decrease in standardized mortality rate (SMR: the ratio of deaths in 
the RA population to the expected deaths in the general population). 8 studies in the 
review reported SMR (21, 22, 24-29) varying from 0,87 to 2,03. Only one study 
reported SMR < 1 while the other seven studies reported SMR > 1, indicating a higher 
mortality rate among RA-patients compared to the general population. 
 
                                                 
1
 Incidence mortality rate = Number of deaths at the end of the study / (mean number of patient during 
study * mean patient follow up) 
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1.4 Treatment 
Several national and regional guidelines for management of rheumatoid arthritis exist, 
including recommendations from The American College of Rheumatology (ACR) 
(30) and the European League against Rheumatism (EULAR) (31). The management 
of rheumatoid arthritis rests on several principles. A comprehensive approach to RA-
treatment consists of patient education, physical/occupational therapy and drug 
treatment (31, 32). RCTs have shown positive effect on muscle strength and quality of 
life from physical exercise in RA-patients (33, 34). Moreover, ACR stress the 
importance of patient education and claim it is critical to engage the patient in an 
effective partnership for managing the disease (30). Analgesics and non-steroidal anti-
inflammatory drugs (NSAIDs) are widely used to control RA symptoms. They do not, 
however, alter the progression of the disease. Analgesics reduce pain and NSAIDs 
reduce pain and stiffness. Disease-modifying antirheumatic drugs (DMARDs) are the 
mainstay in the treatment of RA-patients. EULAR recommends starting treatment 
with synthetic DMARDs early and that this may help a significant proportion of 
patients to achieve low disease activity or remission. (31) ACR also state the 
importance of introducing DMARDs in early stages of RA-treatment in their "2012 
Update of the 2008 American College of Rheumatology Recommendations for the Use 
of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of 
RA”(35) (Figure 3). Biologic DMARDs were introduced in the late 1990s and are the 
latest major addition to RA treatment. DMARD-treatment has undergone dramatic 
changes during the last decades, yielding a new therapeutic dimension to RA-
treatment (31). DMARDs have been found to reduce symptoms such as joint swelling 
and pain. Moreover, they decrease acute-phase markers, limit progressive joint 
damage, and improve patient`s general functionality (12).  
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FIGURE 3 Treatment with DMARDs in early RA 
 
 
DMARD = disease-modifying antirheumatic drug; HCQ = hydroxychloroquine; MTX = methotrexate; RA = rheumatoid 
arthritis; TNF = tumor necrosis factor. 
† Patients were categorized based on the presence or absence of 1 or more of the following poor prognostic features: functional 
limitation (eg, Health Assessment Questionnaire score or similar valid tools), extraarticular disease (eg, presence of rheumatoid 
nodules, RA vasculitis, Felty's syndrome), positive rheumatoid factor or anti-cyclic citrullinated peptide antibodies, and bony 
erosions by radiograph. 
‡ Combination DMARD therapy with 2 DMARDs, which is most commonly MTX based, with some exceptions (eg, MTX + 
HCQ, MTX + LEF, MTX + sulfasalazine, and sulfasalazine + HCQ), and triple therapy (MTX + HCQ + sulfasalazine). 
Singh JA, et al.(35) 
 
 
1.5 Cost 
Costing has three basic elements: Identifying cost variables, measurement of the 
quantities of the resource use and assigning a unit price to each cost variable (36). Our 
study is limited to hospital care costs and costs of pharmaceuticals. An analysis of 
total societal cost of a disease involves measuring both direct and indirect cost. Direct 
cost can be divided in two categories: direct medical cost and direct nonmedical cost. 
Direct medical cost includes pharmaceuticals, GP-visits, in-hospital care, out-hospital 
care, rehabilitation and other cost variables that are directly connected to medical 
treatment. Direct nonmedical cost includes travel expenses, home assistance costs and 
other direct cost variables that are not of a medical nature. Indirect cost is often 
limited to production losses and production gains. The method in which to estimate 
production costs remains a much debated topic in the field of economic evaluation. 
Guidelines from Sweden recommend that production costs are estimated using the 
6 
 
Human Capital Approach (HCA), which values production costs based on gross 
earnings. Some argue that HCA leads to an overestimation of the true cost and argue 
that production costs should be estimated using the friction cost method (37, 38). The 
reasoning is that if an individual is taken out of the workforce, losses in production 
will be compensated for, to some degree, by collages or, in the case of long time sick 
leave, by hiring a replacement worker. And that ultimately, someone unemployed will 
enter the workforce leading to production gains (36). The basic idea of the friction 
cost method is that the amount of production loss due to sick leave is limited to the 
time span the organisation needs to restore the initial production level (36, 37). 
According to Drummond (36) the actual cost of any resource use is not the amount of 
money spent, but rather the opportunity cost, defined as the value of the foregone 
benefits that may have been achieved had the resource been available for its best 
alternative use. In lack of opportunity cost we have used Norwegian DRG prices for 
estimating in –hospital care costs and market prices for estimating the cost of 
pharmaceuticals. Data on quantities of resource use related to in-hospital care and 
pharmaceuticals are collected from the Norwegian Patient Registry and the 
Norwegian Prescription Database respectively. 
 
 
1.6 Economic evaluation 
Scarce resources and the development of new and costly treatment are the main 
drivers of health economics. This and a general rise in awareness among 
policymakers of the importance of theoretical foundation of priority decisions have 
led to an increase in the demand for economic analyses in medicine. 
 
A Cost of Illness analysis (COI) is one of many in the wide range of cost analyses. 
Other common cost analyses include Cost Utility Analysis (CUA), Cost Effectiveness 
Analysis (CEA), Cost Minimization Analysis (CMA), Cost Benefit Analysis (CBA) 
and Cost Consequence Analysis (CCA). 
 
CMA compares the cost of interventions that produce identical effect. CBA examines 
the total costs and benefits in monetary terms. CCA lists the cost variables and their 
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consequences separately to allow the end user to focus on the variables that are 
relevant in their case (39).  
 
In medicine, most economical research has taken the form of CUA or CEA. CEA is 
designed to assess the comparative effects and expenditures of two or more health 
interventions. This involves estimating the incremental cost and effect of an 
intervention compared to an alternative- or no intervention (40). The importance of 
CEA is the assessment of the relative impact of these interventions on health in 
environments with limited resources. A useful result of a CEA is the Incremental Cost 
Effectiveness Ratio (ICER) which expresses the additional cost required to obtain one 
unit of health effect from a given intervention when compared to another (41). When 
the intervention under study is both less costly and more effective than the comparator, 
the intervention dominates the alternative and there is no need for the ICER. However, 
the most common case is one where the new intervention is both more effective and 
more costly than its alternative. Interventions with a low ICER would then have high 
priority for resources (40). Hence, CEA and the ICER are useful to decision makers 
for priority setting. CUA is similar to CEA in many ways and share the characteristics 
described above, but where CEA measures effect in program specific natural units 
related to the program, CUA measures effect in Quality Adjusted Life Years 
(QALYs) or other generic units. This quality of the CUA allows for comparison 
across a broad set of interventions (36).  
 
 
1.7 Cost of Illness 
A COI – analysis measures the economic burden of a disease and estimate the 
maximum amount that could potentially be saved or gained if a disease were to be 
eradicated. (42) There are two main approaches to COI analysis. The prevalence- and 
the incidence approach. A prevalence based analysis includes all costs incurred in a 
given year and yield accurate costs based on observed data. The prevalence approach 
yields a measure of total annual costs. With an incidence approach, the analysis is 
based on all new episodes in a given year and all costs related to the new episodes are 
measured. Additionally, all future costs are estimated for the same patient group and 
converted to the present value and added to the cost incurred in the index year. The 
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advantage of the latter approach is that it provides projections of future costs. Such 
projections, however, may be uncertain (43). COI can identify where the major 
burden of cost might lie in the treatment and care of patients with a certain disease 
(44). COI may also be useful in funding of health care services and setting priority for 
research (43). Moreover, COI studies provide valuable information for cost-
effectiveness and cost-benefit analyses. There are, however, limitations to the use of 
CIO studies. COI does not include any measurement of health effects of the disease. 
Nor does it include the benefits from treatment. Unlike CEA, COI does not aim to 
inform choices on which treatment program is more cost effective. Hence, it cannot, 
in itself, justify allocation of resources in priority decisions (43, 44).  
 
 
1.8 Literature review of RA cost studies 
In order to get an overview of studies on costs of rheumatoid arthritis, we performed a 
search (2013.10) in the Medline database using the following search terms in title and 
abstract: 
 
 Rheumatoid arthritis 
 RA 
 Cost 
 Burden of illness 
 Burden of disease 
 
The search was built to include articles that contain “Rheumatoid arthritis” or “RA” 
and at least one of the other 3 keywords and was limited to the time interval 
01.01.2003 – 31.12.2013. The search generated 994 hits of which 6 (42, 45-49) were 
considered relevant based on the following inclusion criteria: 
 
 The study is conducted in Europe or North America. 
 The study is conducted in the time period: 2000 – 2013. 
 The study includes direct cost of RA. 
 The article is written in English. 
 The study includes estimates on hospital cost and cost of pharmaceuticals 
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A summary of the studies and results is presented in table 1. Currency conversion is 
based on annual average exchange rates from the Norwegian National Bank
2
. The 
present value of historic costs is calculated using actual inflation rates extracted from 
Statistics Norway`s online database
3
. 
 
 
TABLE 1 Studies of cost in rheumatoid arthritis 2003 - 2013 
Author Published 
Year of 
data 
collection 
Study area 
       
      
Hospital 
care        
Pharmaceutical 
       
Guillemin et al. 2004 2000 France 41 398 25 130 5 171 
Westhovens et 
al.* 
2005 2000 Belgium 68 723 5 975 8 960 
Franke et al.*** 2009   Europe 58 443     
Huscher et al. 2006 2002 Germany 42 895 20 356 16 381 
Jacobsson et al. 2007 2001 Sweden 47 333 12 357 21 645 
Kvamme et 
al.** 
2012 2000-2012 Norway 51 011 18 630 19 122 
Average       51 634 16 490 17 820 
 
  Mean annual cost in 2012 NOK 
* An average of early and late rheumatoid arthritis 
** Weighted average of patients on synthetic and biologic DMARDs 
*** A systematic review 
 
 
Despite the similarities in economic status between the countries in this literature 
review, it is likely that there are differences in resource use and price levels. Hence, 
comparing costs must be done with caution. 
 
The latest Norwegian study on the cost of Rheumatoid Arthritis was performed by 
Kvamme and co-workers. (48). The main objective of their study was to estimate the 
total cost for patients with rheumatoid arthritis, ankylosing spondylitis and psoriasis 
                                                 
2
 http://www.norges-bank.no/no/prisstabilitet/valutakurser 
3
 https://www.ssb.no/statistikkbanken/selectvarval/Define.asp?subjectcode=&ProductId=&MainTable= 
KpiAar&nvl=&PLanguage=0&nyTmpVar=true&CMSSubjectArea=priser-og- 
prisindekser&KortNavnWeb=kpi&StatVariant=&checked=true 
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arthritis. Their main data source was the Norwegian DMARD register (NOR 
DMARD) which records resource use among patients starting therapy with synthetic 
and biologic DMARDs. The total annual costs per patient of RA were estimated to € 
36,826 in 2010 EUROs or 313,119 in 2012 Norwegian Kroner (NOK). Using the 
human capital method to calculate the production loss, production losses were the 
largest cost component followed by the cost of biologic DMARDs and the cost of in-
hospital treatment. When the friction cost method was used, biologic DMARDs 
represented the largest cost component followed by production loss. Direct costs were 
estimated at NOK51,011 per patient, of which NOK18,630 was attributable to 
hospital care and NOK19,122 pharmaceuticals. The study covered the two first years 
of treatment. The authors found that the costs were declining during this period, 
hence, the total annual cost estimates in this study may be higher than the average 
annual costs of RA-patients. Moreover, all patients in the NOR-DMARD registry are 
treated with DMARDs, thus, the cost of pharmaceuticals in this study is likely to be 
higher than for the average RA-patient.  
 
Jacobssen and co-workers (47) surveyed a representative sample (n=895) patients 
living in the city of Malmo, Sweden, during 2002. The objective of the study was to 
estimate the cost of living with RA. The authors estimated the mean annual direct cost 
to 44,485 Swedish kroner (SEK) or NOK47,333 (in 2012 NOK). Annual hospital 
costs were estimated to NOK12,357 per patient and annual cost of pharmaceuticals 
were estimated to NOK21,645 per patient. The authors state that their estimates are 
higher than earlier studies and suggest that the reason may be that they have a bottom 
up perspective, yielding more cost variables. The authors also point to the increase in 
medication cost compared to earlier studies and state that costs have increased from 
4% to 18.8% of total cost compared to similar studies in Sweden in the 1980s and 
1990s and that the main explanation is the introduction of TNF-inhibitors in the 
treatment of RA-patients. 
 
Huscher and co-workers (42) estimated the direct and indirect cost of rheumatoid 
arthritis in Germany. They used the National Database of the German Collaborative 
Arthritis Centres to compute the cost and found that mean direct cost amounted to 
NOK42,895 and that of this, NOK20,356 was attributable to hospital care and 
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NOK16,381 to pharmaceuticals. The authors state that their findings are in line with 
those of other cost of illness-studies and that their estimates underline the high 
economic burden of RA.  
 
Guillemin and co-workers (46) performed a cost of illness study of rheumatoid 
arthritis-patients in France. They collected data through a cross sectional study among 
rheumatologists in 148 hospitals and found that social cost represented 41% of total 
cost and that direct cost represented 59%. Annual direct cost per patient amounted to 
NOK41,398 of which 60 % or NOK25,130 was attributable to hospitalization. Annual 
cost of pharmaceuticals were reported at NOK5,171 per patient, however, this 
estimate does not take in to account the cost of TNF-inhibitors that were introduced in 
France at the time. This might explain why the cost estimate for pharmaceuticals in 
this study is significantly lower than that of the other studies in the review.  
 
Additionally, in 2013, Lærum and co-workers produced a comprehensive report on 
the musculoskeletal diseases in Norway in terms of prevalence and societal costs.(50) 
This report, however, only present aggregated costs estimates. 
 
 
2. Objective  
The overarching aim of this thesis was to estimate the cost of pharmaceuticals and 
hospital care among patients with rheumatoid arthritis in Norway. More specifically 
we aim to explore the following research questions: 
 
 What are the total costs of pharmaceuticals and hospital care of rheumatoid 
arthritis in Norway 
 What are the differences in costs across the regional health authorities 
 What are the differences in costs across patient`s sex 
 What are the changes in costs from 2009 – 2012 
 What is the prevalence of rheumatoid arthritis in Norway 
 
Additionally we aim to explore the use of biologics among rheumatoid arthritis 
patients in Norway during the period 2009 - 2012. 
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3. Methods 
We used a prevalence approach to this analysis limited to hospital costs and cost of 
pharmaceuticals. The analysis is based on observed data from the Norwegian Patient 
Registry and the Norwegian Prescription Database. 
 
In accordance with the societal perspective of this analysis, all costs are presented 
without value added tax as this represents a transfer cost and not a cost to society. All 
costs are expressed in 2012 NOK and the present value of historic costs was 
calculated using actual inflation rates (Statistics Norway (SSB)).  
 
Population data was extracted from Statistics Norway (Appendix 12, 13).  
 
 
3.1 Data 
 
3.1.1 The Norwegian Patient Registry 
The Norwegian Patient Registry (NPR) contains information about all individuals 
who have received- or awaits specialized health care in Norway. NPR receives data 
from specialised health care institutions through standardized reports. The reports are 
based on registrations made by health care personnel. Thus, the system is vulnerable 
to human error. Even though most hospitals have established routines to detect errors 
in the patient data registration, it is unlikely that the information that is reported to 
NPR is perfect. Moreover, some variables in the patient data influence the hospitals 
income. Hence, health care personnel have an incentive to make registrations that are 
financially favourable. 
 
Data on each episode of care in general hospitals (out-patient clinic visit, day care and 
in-patient care), consultations by specialists and treatment at private rehabilitation 
clinics were extracted from the Norwegian Patient Registry. We included only 
episodes with ICD-10 codes «M05 – Seropositive rheumatoid Arthritis» and «M06 – 
Other Rheumatoid Arthritis» as either main diagnosis or secondary diagnoses. Data 
were collected for the period 2009 – 2012. Variables that were included in the data set 
were: 
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 Gender 
 Age (10 year intervals) 
 Residence (Regional Health Authority)  
 Year of care (2009 – 2012) 
 DRG code 
 DRG weight 
 Biologic pharmaceuticals  
 
 
Private rehabilitation clinics represented 0.7% of the episodes, consultations by 
specialists represented 10.0% and 89.3% of the episodes are treatment in general 
hospital. In total, 269,885 episodes were registered during the period. We counted the 
number of rheumatoid arthritis-surgical operations by defining DRG 209C, 209D, 
209E, 209F, 209G, 209O, 218, 219, 220O, 220, 221, 222O, 222P, 222, 223O, 223, 
224O, 224, 225O, 225, 226, 227O, 227, 228O, 228, 229O, 229, 233, 234O and 234 as 
rheumatic surgery. 
 
The NPR is required to anonymise any released data material and, in that regard, 
information about DRG had been deleted in 19,768 of the episodes in our dataset.  
 
We used estimates from the Norwegian DRG-system to estimate the cost of in-
hospital care, out-hospital care and biologic pharmaceuticals administered in hospital. 
DRG is a system that aims to classify hospital episodes in homogenous groups based 
on resource-intensity and medical characteristics. All DRGs are assigned a cost-
weight which expresses the mean cost of all episodes within a DRG relative to the 
average hospital episode. The average episode is given a weight of 1 along with a unit 
price. I will call this price the DRG unit price. The Norwegian DRG cost weights are 
computed based on patient- and accounting data from a representative sample of 
Norwegian hospitals. The system is revised annually to accommodate the changes in 
medical practice and development in medical technology. This entails that DRG 
weights and the DRG unit price vary from year to year. Norwegian hospitals are 
financed, in part, based on activity, and the DRG system is the foundation of this 
scheme (51-54). The Norwegian Health Directorate publishes rules for activity based 
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financing (51-54) annually. These publications include changes in DRG, updated 
DRG-weights and the updated DRG unit price.  
 
2009 was a transition period in the funding of out-patient care. Before 2009, out-
patient clinic care was not included in the activity based funding-scheme, but was 
financed through a fee for service. In 2009, out-patient care was included in the 
activity based funding-scheme, but the unit price for out-patient care and in-hospital 
care were different (51). This meant that for episodes in 2009 with missing 
information about DRG-code, which is the only variable that determine whether the 
episode is out-hospital care or in-hospital care, there was no way to determine 
whether to apply the out-patient unit price or the standard DRG unit price. In total, 
54,250 in-hospital episodes were registered in 2009 of which 5,240 lacked 
information about DRG-code. By 2010, out-patient care was fully integrated in the 
DRG-system.  
 
The DRG unit price (Appendix 15) served as our multiplier in the costing of hospital 
care. DRG-weight for each episode was multiplied with the unit price for the relevant 
year and the statistical software SPSS was used to aggregate estimates to patient level. 
By assuming that missing DRG values were out-patient care, the cost estimates for 
2009 appeared to be greatly underestimated (Table 2). Assuming standard unit price 
yielded estimates that appeared to be more in line with the estimates for the following 
years. However, it is likely that this assumption results in an overestimation of the 
true cost since it is likely that at least some episodes are out-patient care. 
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TABLE 2 Total annual cost of hospital care (2012 NOK) 
  
Western 
Norway 
RHA 
Central 
Norway 
RHA 
Northern 
Norway 
RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
2009** 61 947 122 31 289 701 19 902 272 225 206 951 17 612 338 363 658 
2009* 123 700 156 74 699 752 49 288 775 337 998 125 580 358 586 267 166 
2010 119 122 555 74 261 810 44 552 900 347 919 088 659 598 586 515 950 
2011 119 388 173 81 058 851 45 615 273 364 193 702 537 231 610 793 229 
2012 119 932 129 78 686 430 43 468 278 345 036 975 453 121 587 576 932 
*Assumed that the episodes of care was out-patient care when the DRG-code was not stated 
** Assumed that the episodes of care was in-hospital care when the DRG-code was not stated 
 
 
The unit price for consultations by specialists were extracted from fee schedule for 
private practice (55). We assumed that consultation duration exceeded 20 minutes for 
all patients in this study which means a somewhat higher fee. In addition to the 
variable fee, the specialists receive an operating grant. The size of the grant depends 
on the specialist`s need for working space, technical equipment and auxiliary 
personnel. We assumed that on average rheumatic specialists receive a grant of 
NOK864,420, which represent the second of the three 2011/2012 operating grant 
classes
4
. We assumed that, on average, physicians have 2500 consultations per year. 
In total, this amounts to a unit price of NOK728.
5
 
 
The unit price for treatment in private rehabilitation clinics is based on observed data 
from “Samdata 2012”. Samdata report only aggregated data, hence, this estimate 
yields a mean cost across all diagnosis combined and may differ from the true mean 
for rheumatoid arthritis-patients. 
 
1. January 2006, the regional health authorities assumed responsibility for financing 
biologic pharmaceuticals. Initially, the regional health authorities` base funding were 
increased to compensate for the added costs and in 2009 self-administered biologic 
pharmaceuticals were included in the activity based funding scheme. The costs of 
self-administered biologic drugs were not, however, covered by the DRG weight, but 
                                                 
4
 Class 1 = NOK744,120 Class 2 = NOK864,420 Class 3 = NOK1,108,140 
5
 Unit price of consultation by specialist: NOK307 + NOK75 + (NOK864,420 / 2500) = NOK727.768 
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financed based on the number of patients on a particular drug in a given year. Thus, 
the costs of these pharmaceuticals are not included in the data from the Norwegian 
Patient Registry, but registered in the Norwegian Prescription database. In 2010 the 
scheme was expanded to include biologic pharmaceuticals that were administered in 
out-patient clinics. Our analysis does not include costs of biologic pharmaceuticals 
administered in outpatient clinics during 2009.  
 
 
3.1.2 The Norwegian Prescription Database 
Data concerning pharmaceuticals that were not administered in hospital were 
extracted from the Norwegian Prescription Database at the Norwegian Institute of 
Public health. The Database contains data about all dispensed drugs in Norway. An 
online search engine was used to extract data on relevant pharmaceuticals. The search 
was built to include number of users, users per 1000 inhabitants, turnover in 
Norwegian crowns and turnover in doses for all relevant pharmaceuticals (Appendix 
1).  
 
The prescription registry does not have a diagnosis variable. It does however have a 
reimbursement code that can be used as a proxy for diagnosis for reimbursement 
drugs. This variable, however, is not available on the web-based search engine, but 
can be purchased on request. For financial reasons, this was not possible for this 
student study. Thus, we only could extract data on total sales for each pharmaceutical 
without any information on diagnosis. The thesis supervisor proposed estimates of the 
proportion of drugs attributable to rheumatoid arthritis.  
 
 
3.2 Software 
All data on analyses were performed in SPSS 20 or Excel 2010. 
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4. Results 
In total, there were 269,885 specialised health care episodes with rheumatoid arthritis 
as the main- or secondary diagnosis during the period 2009 - 2012. There was a 
steady increase in the number of episodes during the period (Appendix 2). The 
majority of patients had seropositive rheumatoid arthritis (ICD 10 diagnosis M05) 
(Table 3). 
 
 
TABLE 3 Number of episodes by ICD-10 diagnoses  
  Main diagnosis Secondary diagnosis 
M05 - Seropositive Rheumatoid Arthritis 173 272 26 266 
M06 - Other Rheumatoid Arthritis 55 781 16 484 
Source: Norwegian Patient Registry 
 
 
Episodes with Rheumatoid arthritis as the secondary diagnosis accounted for 
approximately 50% of hospital costs
6
.  Non-surgical cancer treatment (DRG 410A) 
was the most frequent DRG where rheumatoid arthritis was registered as a secondary 
diagnosis. 
 
In total, 36,170 unique patients received specialised health care with rheumatoid 
arthritis as either main- or secondary diagnosis during the period 2009 – 2012. Among 
whom 71% of patients were women. The sex distribution was stable in time and 
across RHAs (Table 4). Women had on average more episodes than men representing 
74% of episodes during 2009 - 2012. It is likely that all patients diagnosed with 
rheumatoid arthritis will receive specialised health care during the period of 4 years. 
On the basis of the 4-year period prevalence (n=36,170), the prevalence of RA as of 
January 1 2009 would be the period prevalence minus the incident cases during the 
period. The four year incidence was estimated at 25 per 100,000 per year equivalent 
to 100 per 100,000 during the four years. Assuming that all patients with RA had at 
                                                 
6
 2009: 69%, 2010: 54%, 2011: 47%, 2012: 47% 
18 
 
least one episode of care during the period, the point prevalence was 31,247 or 0.65% 
of the population.
7
  
 
 
TABLE 4 Sex by year and regional health authority (RHA) 
  
Western 
Norway 
RHA 
Central 
Norway 
RHA 
Northern 
Norway 
RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
2009 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 
Female 70.3 % 70.8 % 70.0 % 71.6 % 81.7 % 71.1 % 
2010 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 
Female 70.4 % 70.9 % 70.7 % 71.3 % 66.7 % 71.0 % 
2011 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 
Female 71.2 % 72.0 % 71.4 % 71.2 % 61.8 % 71.3 % 
2012 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 
Female 70.8 % 71.3 % 71.2 % 71.3 % 69.3 % 71.2 % 
 
 
The mean age of patients was 62 years
8
 (females: 63, males: 62) and 65% of patients 
were in the age group 50 - 79 and 11% were less than 40 years old. The age 
distribution was similar across the Regional Health Authorities (Figure 4). Detailed 
tables on the age distribution are presented in appendix 3-5.  
 
 
 
 
 
 
 
 
 
 
                                                 
7
 36,170 – (4,922,409 / 100,000 * 100) = 31,247. Assuming an incidence of 25 per 100,000 and that all 
new patients received specialised health care during the period. Population 1 January 2009: 4,779,252 
(SSB) Average population during the period: 4,922,409. (Appendix 12,13) 
8
 Mean age was estimated based on age-group data (Appendix 10).  
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FIGURE 4 Age distribution of patients by regional health authority 
 
 
4.1 Cost of hospital care 
Approximately 97.0% of specialised somatic care costs were attributable to hospital 
care across time (2009 – 2012) and place (regional health authorities) (Appendix 6). 
Hospital care includes day care, in-patient care, out-patient care and treatment with 
biologic DMARDs administered in hospital (Costs for biologic DMARDs 
administered in outpatients clinics are only included for the period 2010-2012). The 
South Eastern Norway RHA account for most of the costs (57%) and The Northern 
Norway RHA account for the smallest part of the costs (8%). Hospital care costs 
amount to NOK12 million per 100,000 inhabitants nationally. From 2011 to 2012 the 
costs per capita dropped 5%. The South Eastern Norway RHA had the highest costs 
per capita (>NOK12 million per 100,000 inhabitants) and the Northern Norway RHA 
had the lowest (<NOK10 million per 100,000 inhabitants).  
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TABLE 5 Cost of hospital care by year and region. All costs in 2012NOK 
  
Western 
Norway 
RHA 
Central 
Norway 
RHA 
Northern 
Norway 
RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
2009* 123 700 156 74 699 752 49 288 775 337 998 125 580 358 586 267 166 
2010 119 122 555 74 261 810 44 552 900 347 919 088 659 598 586 515 950 
2011 119 388 173 81 058 851 45 615 273 364 193 702 537 231 610 793 229 
2012 119 932 129 78 686 430 43 468 278 345 036 975 453 121 587 576 932 
*Assumed that the episodes of care was in-hospital care when the DRG-code was not stated 
 
 
TABLE 6 Cost of hospital care per 100,000 inhabitants by year and region. All 
costs in 2012NOK 
  
Western 
Norway RHA 
Central Norway 
RHA 
Northern 
Norway RHA 
South-Eastern 
Norway RHA 
Total 
2009* 12 315 127 11 153 145 10 610 621 12 565 072 12 141 240 
2010 11 677 131 10 973 511 9 541 543 12 765 595 11 996 026 
2011 11 535 340 11 850 033 9 715 630 13 173 625 12 331 565 
2012 11 417 323 11 366 190 9 196 521 12 308 737 11 708 049 
*Assumed that the episodes of care was in-hospital care when the DRG-code was not stated 
 
 
Cost per patient (Appendix 7) 
 
 
4.2 Cost of private specialist care 
Less than 1% of the total costs were attributable to consultations by specialists. The 
Western Norway RHA and the South-Eastern Norway HRA had the highest 
proportion ranging between 0.6% and 1.1% while the Central Norway RHA had the 
lowest (< 0.1%) (Appendix 6). The South Eastern Norway RHA and the Western 
Norway RHA had the highest costs per capita while the Central Norway RHA had the 
lowest (Table 8). On a national level and across all RHAs except the Northern 
Norway RHA, costs per capita dropped significantly from 2009 (NOK128,000) to 
2010 (NOK77,000). During the remainder of the period there was an increase in costs. 
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TABLE 7 Cost of private specialist services by year and region. All costs in 
2012NOK 
  
Western 
Norway 
RHA 
Central 
Norway 
RHA 
Northern 
Norway 
RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
2009 1 892 233 60 891 171 881 3 992 573 92 492 6 210 069 
2010 924 014 34 726 210 621 2 519 147 91 345 3 779 853 
2011 692 311 47 136 115 631 3 567 612 80 279 4 502 968 
2012 1 050 169 45 122 95 338 4 373 886 140 459 5 704 973 
 
 
TABLE 8 Cost of private specialist services per 100,000 inhabitants by year and 
region. All costs in 2012NOK 
  
Western 
Norway RHA 
Central Norway 
RHA 
Northern 
Norway RHA 
South-Eastern 
Norway RHA 
Total 
2009 188 384           9 091 37 002 148 424 128 607 
2010 90 578 5 131 45 107 92 431 77 309 
2011 66 891 6 891 24 628 129 048 90 912 
2012 99 974 6 518 20 170 156 033 113 677 
 
 
Cost per patient (Appendix 8) 
 
 
4.3 Cost of private rehabilitation clinics 
Approximately 2% of costs were attributable to rehabilitation in private rehabilitation 
clinics. The Northern Norway RHA had the highest proportion (>3%) and the 
Western Norway RHA had the lowest proportion with close to 1% during the whole 
period (Appendix 6) (Table 9). The Northern Norway RHA also had the highest costs 
per capita (>NOK400,000). In comparison, the Western Norway RHA had less than 
half of this amount. The costs per capita of care in private rehabilitation clinics 
decreased during the period (Table 10). This trend was similar across all RHAs except 
for a small increase in the Western- and Central Norway RHA from 2010 to 2011.  
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TABLE 9 Cost of private rehabilitation clinics by year and region. All costs in 
2012NOK 
  
Western 
Norway 
RHA 
Central 
Norway 
RHA 
Northern 
Norway 
RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
2009 2 156 659 2 790 970 2 029 797 7 459 503 456 704 14 893 633 
2010 1 242 530 1 814 094 2 162 002 6 610 259 0 11 828 884 
2011 1 317 635 1 868 646 1 916 560 6 324 648 23 957 11 451 446 
2012 1 173 893 1 676 990 1 964 474 5 198 669   10 014 026 
 
 
TABLE 10 Cost of private rehabilitation clinics per 100,000 inhabitants by year 
and region. All costs in 2012NOK 
  
Western 
Norway RHA 
Central Norway 
RHA 
Northern 
Norway RHA 
South-Eastern 
Norway RHA 
Total 
2009 214 709 416 710 436 964 277 307 308 438 
2010 121 800 268 065 463 019 242 539 241 936 
2011 127 310 273 178 408 210 228 775 231 198 
2012 111 753 242 240 415 621 185 456 199 539 
 
 
Cost per patient (Appendix 9) 
 
 
4.4 Cost of self-administered pharmaceuticals 
Costs of self-administered drugs increased from NOK351 million to NOK414 million 
during 2009 – 2012 (Table 11). Costs per capita varied considerably across regional 
health authorities (Table 13). The Northern Norway regional health authority had the 
highest costs per capita throughout the period with 44% to 69% higher costs than the 
other regions. 
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Table 11 Cost of self-administered pharmaceuticals by year. All costs in 
2012NOK 
Pharmaceutical 2009 2010 2011 2012 
Adalimumab 127 954 886 161 992 386 151 914 913 163 712 090 
Anakinra 0 612 652 503 514 1 610 808 
Azathioprine 453 777 466 928 483 657 500 159 
Cerolizumab Pegol 0 654 263 2 506 738 6 020 753 
Etanercept 209 814 436 192 148 447 180 737 856 189 863 970 
Golimumab 0 22 002 206 40 920 409 37 776 650 
Hydroxychloroquine 1 254 545 1 335 243 1 362 710 1 374 330 
Leflunomid 4 610 065 5 240 620 5 634 012 5 728 882 
Methotrexate 1 848 501 2 304 759 2 718 700 3 171 889 
Sulfalsalazine 5 671 609 5 531 947 5 175 692 4 817 627 
Total 351 607 819 392 289 453 391 958 200 414 577 157 
 
Costs without value added tax 
 
 
4.5 Total costs 
Total costs increased from NOK958 million to NOK1.017 billion during the period 
(Table 12). Costs per capita increased marginally during the period (Table 13). Both 
total costs and costs per capita decreased from 2011 to 2012. Hospital care accounts 
for the largest proportion of costs (57.7% - 61.1%) and self-administered 
pharmaceuticals represent the second largest cost component (36.7% - 40.7%) 
(Appendix 6).  
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TABLE 12 Total costs by cost variable, year and region. All costs in 2012NOK 
  
Western 
Norway RHA 
Central 
Norway RHA 
Northern 
Norway RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
Cost of hospital care (including pharmaceuticals administered in hospital)   
2009 123 700 156 74 699 752 49 288 775 337 998 125 580 358 586 267 166 
2010 119 122 555 74 261 810 44 552 900 347 919 088 659 598 586 515 950 
2011 119 388 173 81 058 851 45 615 273 364 193 702 537 231 610 793 229 
2012 119 932 129 78 686 430 43 468 278 345 036 975 453 121 587 576 932 
Cost of private specialist care         
2009 1 892 233 60 891 171 881 3 992 573 92 492 6 210 069 
2010 924 014 34 726 210 621 2 519 147 91 345 3 779 853 
2011 692 311 47 136 115 631 3 567 612 80 279 4 502 968 
2012 1 050 169 45 122 95 338 4 373 886 140 459 5 704 973 
Cost of care in private rehabilitation clinics       
2009 2 156 659 2 790 970 2 029 797 7 459 503 456 704 14 893 633 
2010 1 242 530 1 814 094 2 162 002 6 610 259 0 11 828 884 
2011 1 317 635 1 868 646 1 916 560 6 324 648 23 957 11 451 446 
2012 1 173 893 1 676 990 1 964 474 5 198 669   10 014 026 
Cost of patient-administered pharmaceuticals       
2009 75 366 120 45 203 832 52 078 932 178 958 934   351 607 819 
2010 80 000 424 50 731 066 57 508 837 204 049 125   392 289 453 
2011 77 853 086 50 348 473 55 802 554 207 954 087   391 958 200 
2012 80 634 049 55 771 934 54 983 266 223 187 909   414 577 157 
Total             
2009 203 115 168 122 755 446 103 569 385 528 409 135 1 129 554 958 978 688 
2010 201 289 523 126 841 695 104 434 361 561 097 619 750 942 994 414 140 
2011 199 251 205 133 323 106 103 450 017 582 040 048 641 466 1 018 705 843 
2012 202 790 239 136 180 476 100 511 355 577 797 439 593 580 1 017 873 089 
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TABLE 13 Total costs per 100,000 inhabitants by cost variable, year and region. 
All costs in 2012NOK 
  
Western 
Norway RHA 
Central Norway 
RHA 
Northern 
Norway RHA 
South-Eastern 
Norway RHA 
Total 
Cost of hospital care (including pharmaceuticals administered in hospital)   
2009 12 315 127 11 153 145 10 610 621 12 565 072 12 141 240 
2010 11 677 131 10 973 511 9 541 543 12 765 595 11 996 026 
2011 11 535 340 11 850 033 9 715 630 13 173 625 12 331 565 
2012 11 417 323 11 366 190 9 196 521 12 308 737 11 708 049 
Cost of private specialist care       
2009 188 384 9 091 37 002 148 424 128 607 
2010 90 578 5 131 45 107 92 431 77 309 
2011 66 891 6 891 24 628 129 048 90 912 
2012 99 974 6 518 20 170 156 033 113 677 
Cost of care in private rehabilitation clinics     
2009 214 709 416 710 436 964 277 307 308 438 
2010 121 800 268 065 463 019 242 539 241 936 
2011 127 310 273 178 408 210 228 775 231 198 
2012 111 753 242 240 415 621 185 456 199 539 
Cost of patient-administered pharmaceuticals      
2009 7 503 170 6 749 218 11 211 271 6 652 794 7 281 586 
2010 7 842 137 7 496 423 12 316 214 7 486 823 8 023 507 
2011 7 522 201 7 360 468 11 885 427 7 522 121 7 913 412 
2012 7 676 216 8 056 210 11 632 731 7 961 933 8 260 858 
Total           
2009 20 221 390 18 328 164 22 295 857 19 643 597 19 859 872 
2010 19 731 646 18 743 130 22 365 883 20 587 388 20 338 779 
2011 19 251 743 19 490 571 22 033 895 21 053 570 20 567 088 
2012 19 305 266 19 671 158 21 265 044 20 612 158 20 282 124 
 
 
4.6 Biologic pharmaceuticals 
Costs of pharmaceuticals administered in hospital increased dramatically from 2010 
to 2011 and decreased from 2011 to 2012 (Table 14). Cost estimates for 2009 are not 
included since infusion treatment in out-patient clinics was not a part of the activity 
based funding scheme and not included in our data.  
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TABLE 14 Costs of biologic pharmaceuticals administered in hospital (i.v.) by 
year and pharmaceutical. All costs in 2012NOK 
Pharmaceutical 2010 2011 2012 
Abatacept 16 955 960 22 850 998 19 906 233 
Infliximab 69 983 751 70 172 956 60 200 820 
Rituximab 31 365 291 40 101 736 42 145 922 
Tociluzumab 18 965 691 32 302 742 41 424 699 
Total 137 270 692 165 428 432 163 677 674 
 
 
Etanercept is the most common biologic pharmaceutical among rheumatoid arthritis-
patients (Table 15). More than 3000 unique patients received Etanercept during 2010 
– 2012 while only 55 patients received treatment with Anakinra. In total, the number 
of unique patients who received treatment with biologic pharmaceuticals increased 
from 3792 to 4323 during 2010 – 2012 (Table 16). More than 200 unique patients 
received treatment with at least two biologic pharmaceuticals in the same year during 
2010 – 2012. The most frequent combinations were Infliximab – Rituximab, 
Infliximab – Tociluzumab and Adalimumab – Etanercept (Table 18) and this was 
consistent during the period. In total, 73 unique patients received treatment with 3 or 
more biologic pharmaceuticals during the same year. The most frequent drug-
combination was Abatacept, Infliximab and Tociluzumab (Table 17). 
 
 
TABLE 15 Number of unique patients on biologic DMARDs by type of biologic 
and year 
Pharmaceutical  
Type of 
administration 
2010 2011 2012 
2010 - 
2012 
Rituximab i.v 714 826 890 1233 
Abatacept i.v 172 159 149 260 
Etanercept s.c 1353 1724 1808 3011 
Infliximab i.v 903 735 674 1152 
Adalimumab s.c 725 566 512 1116 
Golimumab s.c 4 249 181 349 
Anakinra s.c 25 27 21 55 
Tociluzumab i.v 208 267 344 503 
i.v=Intraveneous, s.c=subcutaneous 
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TABLE 16 Number of unique patients on biologic DMARDs by period and the 
number of different drugs. 
Number of 
different drugs 
2009 2010 2011 2012 2009 - 2012 
1 2801 3501 3937 4085 5419 
2 173 270 268 221 1082 
3 9 21 24 16 238 
4 0 0 2 1 65 
5 0 0 0 0 8 
6 0 0 0 0 1 
7 0 0 0 0 0 
8 0 0 0 0 0 
 
 
TABLE 17 Number of unique patients on three biologic pharmaceuticals in the 
same year by drug combination 
Combination of biologic pharmaceutical Number of unique patients 
Abatacept, Infliximab, Tociluzumab 13 
Etanercept, Infliximab, Adalimumab 8 
Rituximab, Etanercept, Infliximab 7 
Rituximab, Infliximab, Tociluzumab 6 
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TABLE 18 Number of unique patients who were on multiple biologic 
pharmaceuticals in the same year by year and drug combination. 
2009 Adminitrated Rituximab Abatacept Etanercept Infliximab Adalimumab Golimumab Anakinra Tociluzumab 
Rituximab i.v 
        
Abatacept i.v 12 
       
Etanercept s.i 12 5 
      
Infliximab i.v 36 22 12 
     
Adalimumab s.i 8 3 35 22 
    
Golimumab s.i 0 0 0 0 0 
   
Anakinra s.i 1 0 0 1 0 0 
  
Tociluzumab i.v 6 6 7 10 2 0 0 
 
  
         
2010 Adminitrated Rituximab Abatacept Etanercept Infliximab Adalimumab Golimumab Anakinra Tociluzumab 
Rituximab i.v 
        
Abatacept i.v 13 
       
Etanercept s.i 19 2 
      
Infliximab i.v 40 28 26 
     
Adalimumab s.i 14 9 48 17 
    
Golimumab s.i 0 0 0 0 0 
   
Anakinra s.i 0 0 3 0 1 0 
  
Tociluzumab i.v 21 32 8 41 10 1 1 
 
  
         
2011 Adminitrated Rituximab Abatacept Etanercept Infliximab Adalimumab Golimumab Anakinra Tociluzumab 
Rituximab i.v 
        
Abatacept i.v 10 
       
Etanercept s.i 28 6 
      
Infliximab i.v 25 17 34 
     
Adalimumab s.i 10 3 46 12 
    
Golimumab s.i 8 2 22 7 5 
   
Anakinra s.i 0 0 5 4 2 7 
  
Tociluzumab i.v 22 20 14 31 6 1 1 
 
  
         
2012 Adminitrated Rituximab Abatacept Etanercept Infliximab Adalimumab Golimumab Anakinra Tociluzumab 
Rituximab i.v 
        
Abatacept i.v 8 
       
Etanercept s.i 22 4 
      
Infliximab i.v 23 13 21 
     
Adalimumab s.i 8 0 37 2 
    
Golimumab s.i 3 2 17 3 5 
   
Anakinra s.i 0 0 1 0 2 0 
  
Tociluzumab i.v 17 21 13 44 5 1 1 
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In total, 6813 unique patients received treatment with biologic pharmaceuticals during 
the period 2009 – 2012. 5944 patients received only one biologic during the same 
year. 481 of these patients changed pharmaceutical from one year to the next (Table 
19).  
 
 
TABLE 19 Number of patients who changed between biologics from one year to 
the next by type of biologic pharmaceutical.  
    Changed from 
    Abatacept Adalimumab Anakinra Etanercept Golimumab Infliximab Rituximab Tociluzumab 
Changed 
to 
Abatacept - 5 0 7 1 2 12 4 
Adalimumab 2 - 0 43 0 4 2 0 
Anakinra 0 1 - 3 1 0 0 0 
Etanercept 5 56 2 - 5 21 5 5 
Golimumab 2 5 4 8 - 8 5 1 
Infliximab 2 3 0 14 0 - 3 1 
Rituximab 3 53 0 67 4 27 - 1 
Tociluzumab 6 15 1 30 4 6 22 - 
 
 
4.7 Episodes of surgery 
The number of surgical operations for inflammatory rheumatic joint disease registered 
with surgical DRGs (Appendix 11) decreased from 2009 to 2010 and increased during 
2010 – 2012 (Table 20). From 2011 to 2012 the number of episodes in surgical DRGs 
increased by 27%.  
 
 
TABLE 20 Number of episodes of surgery 
Year Male Female Total 
2009 31 387 418 
2010 28 340 368 
2011 29 382 411 
2012 26 496 522 
 
 
4.8 Trends in type of care (In-hospital care, day care and out-patient care) 
In-hospital care and day care had a negative trend during the period in terms of costs 
and the number of registered episodes while out-patient care had a positive trend 
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(Table 21-22, figure 4-5). The number of out-patient episodes increased from 37,000 
to 47,000 from 2009 to 2010 and costs increased from NOK50 million to NOK143 
million during the same period. The estimates in 2009, however, are likely to be lower 
than the true costs since out-patient administered biologic pharmaceuticals were not 
included in the activity based funding scheme in 2009 and thus are not included in our 
dataset. 
 
 
TABLE 21 Hospital care costs by type (In-hospital, Out-hospital and Day care), 
year and RHA. All costs in 2012NOK 
 
2 009 2 010 2 011 2 012 
Western Norway RHA 
In-hospital care and day care 49 629 884 35 919 081 31 620 505 33 955 956 
Out-patient care 7 036 527 26 923 837 35 437 710 32 919 117 
Central Norway RHA 
In-hospital care and day care 22 174 270 16 598 609 16 626 913 14 217 378 
Out-patient care 6 087 063 16 083 892 24 533 444 24 535 374 
Northern Norway RHA 
In-hospital care and day care 10 396 889 8 127 648 7 071 202 5 496 670 
Out-patient care 7 526 694 12 477 962 16 872 417 17 257 515 
South-Eastern Norway RHA 
In-hospital care and day care 179 767 340 155 199 333 140 256 888 125 855 479 
Out-patient care 29 542 871 87 683 541 128 702 687 123 724 983 
 
 
FIGURE 5 Hospital care costs by type (In-hospital, Out-hospital and Day care) 
and Year 
 
 
0
50 000 000
100 000 000
150 000 000
200 000 000
250 000 000
300 000 000
2 009 2 010 2 011 2 012
In-hospital care and day care
Out-patient care
31 
 
TABLE 22 Hospital episodes by type (In-hospital, Out-hospital and Day care), 
year and RHA 
  2009 2010 2011 2012 
Western Norway RHA 
Out patient care 4 870 6 935 7 128 7 762 
In-hospital care and day care 2 750 1 305 1 112 1 176 
Central Norway RHA 
Out patient care 5 026 6 550 7 396 7 611 
In-hospital care and day care 1 095 364 345 303 
Northern Norway RHA 
Out patient care 3 715 4 164 4 383 4 478 
In-hospital care and day care 798 257 220 172 
South-Eastern Norway RHA 
Out patient care 22 666 30 185 33 832 35 553 
In-hospital care and day care 8 090 4 305 3 393 3 110 
 
 
FIGURE 6 Hospital episodes by type (In-hospital, Out-hospital and Day care), 
year and RHA 
 
 
 
4.9 Distribution of hospital care costs 
The median cost of hospital care per patient was NOK12,268 and the mean cost of 
hospital care per patient was NOK67,709. 12.5% of costs were attributable to the 1% 
most costly patients. 
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5. Discussion 
The results of this study indicate that approximately 31,250 patients suffered from 
rheumatoid arthritis as of 1 January 2009. The disease poses a considerable financial 
burden on society with costs of more than NOK1 billion in 2012 for hospital care and 
pharmaceuticals. In 2012, hospital care costs, private specialist costs and costs of 
rehabilitation in private rehabilitation clinics amounted to NOK603 million or 0.5% of 
specialised health care expenditures
9
. Hospital care represents the largest cost 
component (57.7% - 61.1% of total costs). Self-administered pharmaceuticals 
represent the second largest cost component (36.7% - 40.7%) and increased from 
NOK351 million in 2009 to NOK414 million in 2012.  
 
 
5.1 Strengths and limitations 
An important strength of this study is the comprehensive data set that in principal 
captures all episodes of care for RA patients during four years. The validity of the 
variables age and sex is supposedly high. Unfortunately, the data set has several 
weaknesses that should be taken into consideration when interpreting the findings. 
 
Husher and co-workers (42) define COI – analysis as an estimate of the maximum 
amount of money that could potentially be saved or gained if a disease were to be 
eliminated. In this regard, our study is limited in the sense that rheumatoid arthritis 
may cause other complications such as cardiovascular disease, respiratory diseases, 
cancer and infections. These conditions incur costs, but in treating these conditions 
rheumatoid arthritis might not always be registered as the main- or secondary 
diagnosis. Our study is also limited in that we only included cost of hospital care and 
pharmaceuticals. Previous studies indicate that indirect cost (production losses) 
account for a significant proportion of the total societal cost of rheumatoid arthritis 
(42, 45-48, 56-58). Moreover, primary care costs and direct non-medical costs are not 
included in our analysis. Additionally, some variables that are included in the analysis 
may be over- or underestimated. Out-patient administered biologic pharmaceuticals 
are not included for 2009 leading to an underestimation of hospital care costs. 
                                                 
9
 Specialised health care expenditures in 2012 = NOK116 billion. (SSB) 
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Moreover, missing information about DRG lead to uncertain cost estimates for 2009 
due to differences in DRG unit prices for out-patient care and in-hospital- and day 
care. The unit price for private specialist care is based on assumptions about 
rheumatologists’ activity and operating grant which are uncertain and may lead to an 
over- or underestimation of the true costs. The costs of private rehabilitation care are 
based on aggregated data and are also uncertain. 
 
Cost estimates include episodes of care with rheumatoid arthritis as either the main- 
or the secondary diagnosis and some episodes may not be caused in full by 
rheumatoid arthritis. This may lead to an overestimation of the costs that are 
attributable to rheumatoid arthritis.  
 
An overarching limitation in our study is that the costs may not represent opportunity 
cost estimates. In economics, the true cost of a resource is its value in the best 
alternative project. Due to imperfections in the market for health care, no unit costs 
represent the opportunity costs.  
 
The basis for estimating the unit cost for hospital care was the Norwegian DRG 
system. This system has two main possible sources of error. Firstly, the DRG weights 
and the unit price may not reflect the actual resource intensity of patient care. It would 
be utopic to think that the DRG system can keep up with the continuous and rapid 
development in medical technology. Thus, cost estimates based on this system are not 
likely to reflect actual costs perfectly. Moreover, heterogeneous resource intensity 
across patients within each DRG may also result in inaccurate estimates when the 
study sample is small. The DRG system, however, is constructed such that the 
average costs for large patient groups are correctly estimated. Even though the costs 
of the individual episode of care may be biased, the total costs are likely to be correct.   
 
Secondly, the system relies on accurate registrations by health care personnel. In 2011, 
The Norwegian Directorate of Health performed a survey on DRG coding among 
health care personnel. In 14 of 21 health care enterprises, >40 % of health care 
personnel that were responsible for DRG-coding reported inadequate training. 2.2% 
reported knowledge about episodes of deliberate incorrect coding. Because 
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Norwegian hospitals have partly DRG financing, the choice of diagnosis has a direct 
relation to the hospitals` income. Hence, financial consequences may motivate the 
choice of diagnosis. As a result of this, the main- and secondary diagnoses that are 
reported to NPR may not reflect the true condition of the patients and thus yield 
biased data on rheumatoid arthritis-attributable health care consumption. In 2011, a 
revision by NPR
10
 of 4000 randomly selected in-patient care- and day care episodes 
revealed that 19.5% of episodes lacked consistency in main diagnosis-code reported 
to NPR and what was registered in the patient journal. In 4.2% of cases, the main 
diagnosis that was reported to NPR was registered as the secondary diagnosis in the 
patient journal. In 5.6% of the cases the main diagnosis that was reported to NPR was 
not registered as main- or secondary diagnosis in the patient journal.
11
  
 
Since the data on hospital episodes were not date-specific we were not able to reveal 
simultaneous use of multiple biologic pharmaceuticals. Patients who received more 
than one type of pharmaceutical during one year may have used them simultaneously 
or simply changed from one pharmaceutical to another.  
 
We did not have access to diagnosis-specific data on consumption of patient-
administered biologic pharmaceuticals. Data from the Norwegian Prescription 
Database were aggregated to yield total consumption independent of diagnosis. This 
meant that we had to use uncertain estimates of the proportion of drugs attributable to 
rheumatoid arthritis which in turn led to uncertainty in the cost estimates for patient-
administered biologic pharmaceuticals. 
 
 
5.2 Discussion of findings 
Hospital care costs increased during the period 2009-2011 before decreasing in 2012. 
The lack of data on out-patient administered biologic pharmaceuticals may explain 
some of the difference between the 2009- and 2010 cost estimates. Despite an 
                                                 
10
 http://www.helsedirektoratet.no/kvalitet-planlegging/helsefaglige-
kodeverk/kodeveiledning/Sider/nasjonal-gjennomgang-av-medisinsk-kodepraksis.aspx 
11
 http://www.helse-vest.no/aktuelt/rapporter/Documents/Internrevisjonsrapportar/HVIR_2011-
Nasjonal-internrevisjon-av-medisinsk-kodepraksis-hovedrapport.pdf 
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increase in the number of patients and episodes of care, costs dropped from NOK610 
million in 2011 to NOK587 million in 2012. One reason for this is that the DRG-
weights for the most common DRGs in rheumatoid arthritis-treatment decreased 
(Table 23). If the adjustments of the DRG weights reflect an actual change in resource 
intensity of RA treatment, our estimates are correct and costs have in fact decreased. 
However, it could also be the case that our cost estimates for the period 2009-2011 are 
higher than the true cost or that the cost estimates for 2012 are lower than the true cost.  
 
 
TABLE 23 Change in DRG-weight 2011 - 2012 
DRG Frequency* Percent** 
Cumulative 
percent 
Weight 
2011 
Weight 
2012 
Change 2011 
- 2012 
908C 90667 34 34 0,032 0,025 -22 % 
908O 29045 11 44 0,042 0,033 -21 % 
808H 25017 9 54 0,482 0,435 -10 % 
908R 20142 7 61 0,031 0,022 -29 % 
808V 13069 5 66 0,043 0,040 -7 % 
410A 6669 2 68 0,214 0,214 0 % 
242C 5769 2 71 0,706 0,733 4 % 
* Number of episodes of care during 2009 - 1012 
** Percent of total number of episodes of care during 2009 - 2012 
 
 
Hospital care costs were more than 30% higher per capita in the South Eastern 
Norway RHA compared to the Northern Norway RHA during the period 2010 – 2012. 
The reasons for the regional differences in hospital care costs are not explored in this 
study, but deserve future research.  
 
Costs of care in private rehabilitation clinics differed across regional health 
authorities. Demand for private rehabilitation services are likely to be influenced by 
supply and it is possible that some of the variation is due to differences in the number 
of private rehabilitation clinics across regions. Similarly, the differences in costs of 
private specialist care may be a result of differences in accessibility of specialists 
across regions.  
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Costs of self-administered pharmaceuticals increased during the period. Costs of 
biologic pharmaceuticals administered in hospital increased considerably from 2010 
to 2011 but decreased from 2011 to 2012. The latter finding was an unexpected one as 
treatment with biologic pharmaceuticals has proven effective among rheumatoid 
arthritis patients. The majority of episodes related to hospital administered biologic 
pharmaceuticals are registered in DRG 808H. The weight for DRG 808H decreased 
by 10% from 2011 to 2012 which directly affects the cost estimate thus indicating that 
the reduction in costs does not necessarily mirror the trends in consumption. When we 
examined the number of patients who received biologic pharmaceuticals we found 
that treatment with biologics increased during 2009 - 2012.  
 
The number of episodes registered with surgical DRGs also increased during the 
period and we found no indications of a trade-off between pharmaceuticals and 
surgery. We did find, however, that women had on average more surgery than men 
representing more than 90% of surgeries. 
 
The number of out-patient care episodes increased dramatically in the period and the 
number of day care and in-hospital care episodes decreased. From 2009 to 2010 out-
patient care episodes increased by 31%. This can be explained, at least in part, by the 
inclusion of out-patient administered biologic drugs in the activity based funding 
scheme in 2010. 
 
Our study yields high hospital cost estimates compared what is reported by other 
studies (42, 46-49). As discussed in the literature review, there are methodological 
differences across the studies that may explain some of the variation. Different time 
periods may also explain some of the difference. The studies by Guillemin and co-
workers, Husher and co-workers, Jacobsen and co-workers, and Westhovens and co-
workers are based on data collected in the early 2000s. It is approximately 10 years 
between these studies and our study during which there has been considerable 
development in RA-treatment. Moreover, Norway is of the countries in the world with 
the highest health care costs. This may also contribute to the difference. 
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The findings of this study indicate that during 2009-2012 in total 36,170 unique 
patients received care in somatic hospitals with RA as the main or supplementary 
diagnosis. This number, however, also included those who did not have the disease on 
1
st
 of January 2009, but developed it during the subsequent four years. The incidence 
of RA in Norway has been estimated at 25 per 100,000 per year which means that 
36,170 is an overestimate of the point prevalence (14). Detracting 4,923 based on the 
four year cumulative incidence, the number is down to 31,247. Patients who did not 
have any episodes of care during the period, are not included which means that the 
latter number is somewhat underestimated, but this bias is likely very small. A 
prevalence of 31,247 means that prevalence proportion is 0.65% in Norway. This is in 
line with estimates reported by Symmons and co-workers on the prevalence of RA in 
The United Kingdom (59) and the overall prevalence of RA in developed countries 
(12).  Our estimate is slightly higher, however, than that from a Norwegian study by 
Kvien and co-workers (13). Kvien and co-workers estimated the prevalence based on 
a patient register and a population survey of one county representing approximately 
10% of the Norwegian population. They estimated the prevalence of RA among 
inhabitants between 20 and 79 years of age, whereas our estimate is based on all age 
groups. The differences in methodology may likely explain the difference between 
Kvien’s and our estimate.  
 
A number of cost studies of Rheumatoid Arthritis have been undertaken (42, 45-48, 
56-58), but development in treatment technology, and pharmaceuticals means that it is 
important to update these studies continuously. Though this cost-of-illness study does 
not provide information about the health benefits behind the costs, it may provide 
important cost data for future cost effectiveness studies. 
 
Future cost of illness-studies on rheumatoid arthritis will provide valuable knowledge 
about the continued development of cost over time. However, the scale of RA-costs 
and the scarcity of health care resources lead to the need for making the most of the 
resources at hand. Hence, the main focus of future research should be on identifying 
cost effective interventions through cost effectiveness analyses or cost utility 
analyses.  
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6. Conclusion 
Afflicting more than 31,000 patients, rheumatoid arthritis poses a considerable burden 
on the Norwegian society in terms of hospital costs and costs of pharmaceuticals. In 
total, costs of pharmaceuticals and hospital care amounted to NOK1.018 billion in 
2012. There was an increase in costs during the period 2009-2011 and a small 
decrease from 2011 to 2012. Total costs and costs per capita differed considerably 
across the regional health authorities. The use of biologic pharmaceuticals increased 
during the period. The data do not, however, indicate that the increased use of 
biologics has reduced the use of surgery for rheumatoid arthritis.  
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APPENDIX 
 
Appendix 1 Variables in the data extraction from the Norwegian Prescription 
Database 
Measures 
 Number of users 
 Users per 1000 inhabitants 
 Turnover (NOK) 
 Turnover (Number of doses) 
Pharmaceutical 
L04AB05 Certolizumab pegol 
 
L04AB06 Golimumab 
 
L04AB01 Etanercept 
 
L04AC03 Anakinra 
 
 L04AB04 Adalimumab 
 A07EC01 sulfasalazine 
 L01BA01 Methotrexate 
 L04AX03 Methotrexate 
 L04AA13 Leflunomide 
 P01BA02 Hydroxychloroquine 
 L04AX01 Azathioprine 
Variables 
 Period (2009-2012) 
 Age (0 - 4, 5 - 9, 10 - 14, 15 - 19, 20 - 24, 25 - 29, 30 - 34, 35 - 39, 40 - 44, 45 - 49, 
50 - 54, 55 - 59, 60 - 64, 65 - 69, 70 - 74, 75 - 79, 80 - 84, 85 - 89, 90+) 
 Sex 
 Regional Health Authority 
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Appendix 2 Number of hospital episodes per year 
 Year Number of episodes 
2009 62893 
2010 64642 
2011 69296 
2012 73053 
 
 
Appendix 3 Number of patients per age group 
  Frequency Percent Cumulative Percent 
Not registered 413 1,1 % 1,1 % 
0-19 345 1,0 % 2,1 % 
20-29 992 2,7 % 4,8 % 
30-39 2227 6,2 % 11,0 % 
40-49 4222 11,7 % 22,7 % 
50-59 6981 19,3 % 42,0 % 
60-69 9191 25,4 % 67,4 % 
70-79 7251 20,0 % 87,4 % 
80 + 4548 12,6 % 100,0 % 
Total 36170 100,0 % 
 
 
Based on patient`s age at the time of the first registration 
 
 
Appendix 4 Age distribution by regional health authority 
  
Western 
Norway 
RHA 
Central 
Norway 
RHA 
Northern 
Norway 
RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
Not registered 1,0 % 1,4 % 2,5 % 0,9 % 0,3 % 1,1 % 
0-19 1,1 % 0,9 % 1,5 % 0,8 % 0,9 % 1,0 % 
20-29 3,2 % 2,8 % 3,5 % 2,5 % 3,1 % 2,8 % 
30-39 5,9 % 5,9 % 5,6 % 6,4 % 6,1 % 6,2 % 
40-49 11,6 % 10,1 % 11,8 % 12,1 % 10,1 % 11,7 % 
50-59 17,7 % 20,3 % 18,8 % 19,6 % 22,1 % 19,3 % 
60-69 23,2 % 26,1 % 25,7 % 25,9 % 31,6 % 25,4 % 
70-79 20,5 % 19,4 % 19,6 % 20,1 % 17,8 % 20,0 % 
80 + 15,8 % 13,1 % 10,9 % 11,7 % 8,0 % 12,5 % 
 
Based on patient`s age at the time of the first registration 
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Appendix 5 Sex distribution by age and regional health authority 
  Male Female Not registered Total 
          
Western Norway RHA 
Not registered 11 (0,005) 55 (0,012)   66 (0,01) 
0-19 31 (0,015) 45 (0,009)   76 (0,011) 
20-29 53 (0,026) 166 (0,035)   219 (0,032) 
30-39 117 (0,058) 282 (0,059)   399 (0,059) 
40-49 233 (0,115) 555 (0,116) 1 (0,091) 789 (0,116) 
50-59 375 (0,185) 829 (0,174)   1204 (0,177) 
60-69 518 (0,255) 1058 (0,222) 5 (0,455) 1581 (0,232) 
70-79 430 (0,212) 966 (0,203) 3 (0,273) 1399 (0,205) 
80 + 264 (0,13) 812 (0,17) 2 (0,182) 1078 (0,158) 
Total 2032 (1) 4768 (1) 11 (1) 6811 (1) 
Central Norway RHA 
Not registered 13 (0,009) 53 (0,016)   66 (0,014) 
0-19 11 (0,008) 32 (0,009)   43 (0,009) 
20-29 31 (0,021) 106 (0,031)   137 (0,028) 
30-39 79 (0,054) 207 (0,061)   286 (0,059) 
40-49 155 (0,106) 334 (0,099)   489 (0,101) 
50-59 298 (0,203) 687 (0,203)   985 (0,203) 
60-69 418 (0,285) 846 (0,25)   1264 (0,261) 
70-79 294 (0,201) 645 (0,191)   939 (0,194) 
80 + 166 (0,113) 471 (0,139)   637 (0,131) 
Total 1465 (1) 3381 (1)   4846 (1) 
Northern Norway RHA 
Not registered 14 (0,013) 76 (0,03)   90 (0,025) 
0-19 18 (0,016) 36 (0,014)   54 (0,015) 
20-29 38 (0,034) 89 (0,035)   127 (0,035) 
30-39 63 (0,057) 141 (0,056)   204 (0,056) 
40-49 135 (0,122) 292 (0,116)   427 (0,118) 
50-59 224 (0,202) 458 (0,182)   682 (0,188) 
60-69 316 (0,285) 614 (0,244)   930 (0,257) 
70-79 200 (0,181) 510 (0,203)   710 (0,196) 
80 + 100 (0,09) 296 (0,118)   396 (0,109) 
Total 1108 (1) 2512 (1)   3620 (1) 
Other 
Not registered 1 (0,01)     1 (0,003) 
0-19 2 (0,021) 1 (0,004)   3 (0,009) 
20-29 4 (0,042) 6 (0,026)   10 (0,031) 
30-39 5 (0,052) 15 (0,066)   20 (0,061) 
40-49 10 (0,104) 23 (0,1)   33 (0,101) 
50-59 19 (0,198) 53 (0,231)   72 (0,221) 
60-69 37 (0,385) 65 (0,284) 1 (1) 103 (0,316) 
70-79 15 (0,156) 43 (0,188)   58 (0,178) 
80 + 3 (0,031) 23 (0,1)   26 (0,08) 
Total 96 (1) 229 (1) 1 (1) 326 (1) 
South-Eastern Norway RHA 
Not registered 31 (0,005) 161 (0,011)   192 (0,009) 
0-19 71 (0,012) 102 (0,007)   173 (0,008) 
20-29 118 (0,019) 407 (0,028) 1 (0,2) 526 (0,025) 
30-39 349 (0,057) 990 (0,067)   1339 (0,064) 
40-49 785 (0,128) 1735 (0,118) 1 (0,2) 2521 (0,121) 
50-59 1274 (0,208) 2808 (0,191)   4082 (0,196) 
60-69 1709 (0,279) 3689 (0,25) 1 (0,2) 5399 (0,259) 
70-79 1192 (0,195) 3001 (0,204) 1 (0,2) 4194 (0,201) 
80 + 586 (0,096) 1845 (0,125) 1 (0,2) 2432 (0,117) 
Total 6115 (1) 14738 (1) 5 (1) 20858 (1) 
Proportions in the parenthesis 
Based on patient`s age at the time of the first registration 
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Appendix 6 Proportion of total costs by type of care and region 
Year  
Western 
Norway 
RHA 
Central 
Norway 
RHA 
Northern 
Norway 
RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
Cost of hospital care (including pharmaceuticals administered in hospital)   
2009 60,9 % 60,9 % 47,6 % 64,0 % 51,4 % 61,1 % 
2010 59,2 % 58,5 % 42,7 % 62,0 % 87,8 % 59,0 % 
2011 59,9 % 60,8 % 44,1 % 62,6 % 83,8 % 60,0 % 
2012 59,1 % 57,8 % 43,2 % 59,7 % 76,3 % 57,7 % 
Cost of private specialist care         
2009 0,9 % 0,0 % 0,2 % 0,8 % 8,2 % 0,6 % 
2010 0,5 % 0,0 % 0,2 % 0,4 % 12,2 % 0,4 % 
2011 0,3 % 0,0 % 0,1 % 0,6 % 12,5 % 0,4 % 
2012 0,5 % 0,0 % 0,1 % 0,8 % 23,7 % 0,6 % 
Cost of care in private rehabilitation clinics       
2009 1,1 % 2,3 % 2,0 % 1,4 % 40,4 % 1,6 % 
2010 0,6 % 1,4 % 2,1 % 1,2 % 0,0 % 1,2 % 
2011 0,7 % 1,4 % 1,9 % 1,1 % 3,7 % 1,1 % 
2012 0,6 % 1,2 % 2,0 % 0,9 % 0,0 % 1,0 % 
Cost of self-administered pharmaceuticals       
2009 37,1 % 36,8 % 50,3 % 33,9 % 0,0 % 36,7 % 
2010 39,7 % 40,0 % 55,1 % 36,4 % 0,0 % 39,4 % 
2011 39,1 % 37,8 % 53,9 % 35,7 % 0,0 % 38,5 % 
2012 39,8 % 41,0 % 54,7 % 38,6 % 0,0 % 40,7 % 
 
 
Appendix 7 Costs per patient of hospital care by year and region 
 Year 
Western 
Norway 
RHA 
Central 
Norway 
RHA 
Northern 
Norway 
RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
2009 30 090 28 317 22 978 28 837 8 174 28 362 
2010 29 596 27 073 20 703 29 980 6 467 28 470 
2011 32 522 27 874 21 578 29 935 7 069 29 202 
2012 29 804 26 107 19 607 26 656 5 149 26 406 
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Appendix 8 Costs per patient of private specialist services by year and region 
 Year 
Western 
Norway 
RHA 
Central 
Norway 
RHA 
Northern 
Norway 
RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
2009 460 23 80 341 1 303 300 
2010 230 13 98 217 896 183 
2011 189 16 55 293 1 056 215 
2012 261 15 43 338 1 596 256 
 
 
Appendix 9 Costs per patient of private rehabilitation clinics 
Year  
Western 
Norway 
RHA 
Central 
Norway 
RHA 
Northern 
Norway 
RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
2009 525 1 058 946 636 6 432 721 
2010 309 661 1 005 570 0 574 
2011 359 643 907 520 315 547 
2012 292 556 886 402 0 450 
 
 
Appendix 9B Costs per patient of patient-administered DMARDs. 
Year 
Western 
Norway RHA 
Central 
Norway RHA 
Northern 
Norway RHA 
South-Eastern 
Norway RHA 
Total 
2009 29 383 20 369 32 130 27 344 27 151 
2010 29 796 22 058 34 509 29 591 28 958 
2011 27 096 21 576 32 715 29 237 27 947 
2012 26 381 23 317 32 571 30 267 28 571 
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Appendix 10 Age distribution of patients with at least one episode of care during 
the period 2009 - 2012 
Age group Frequency Percent 
Cumulative 
Percent 
From To 
Assumed 
mean per 
Age 
group 
Tot 
patient 
years 
                
0-19 345 1,0 % 2,1 % 0 19 11,5 3967,5 
20-29 992 2,7 % 4,8 % 20 29 26,5 26288 
30-39 2227 6,2 % 11,0 % 30 39 36,5 81285,5 
40-49 4222 11,7 % 22,7 % 40 49 46,5 196323 
50-59 6981 19,3 % 42,0 % 50 59 56,5 394426,5 
60-69 9191 25,4 % 67,4 % 60 69 65 597415 
70-79 7251 20,0 % 87,4 % 70 79 73,5 532948,5 
80 + 4548 12,6 % 100,0 % 80 99 88,5 402498 
                
Total 35757       Mean 62,50949   
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Appendix 11 Surgical DRGs relevant for patients with rheumatoid arthritis 
DRG-Code DRG-Text 
209C Major joint secondary procedure on hip 
209D Major joint primary procedure on hip w cc 
209E Major joint primary procedure on hip w/o cc 
209F Major joint secondary procedure on knee/ankle 
209G Major joint primary procedure on knee/ankle 
209O Store leddingrep på underekstremitet, ikke reoperasjon, dagkirurgisk behandling 
218 Op på humerus & kne/legg/fot ekskl kneleddsop > 17 år m/bk 
219 Op på humerus & kne/legg/fot ekskl kneleddsop > 17 år u/bk 
220O Op på humerus & kne/legg/fot, dagkirugisk behandling 
220 Op på humerus & kne/legg/fot ekskl kneleddsop 0-17 år 
221 Operasjoner på kneledd ekskl proteseop m/bk 
222O Other knee procedures, short therapy 
222P Major knee procedures, short therapy 
222 Operasjoner på kneledd ekskl proteseop u/bk 
223O Større op på humerus/albue/underarm, dagkirurgisk behandling 
223 Op på humerus/albue/underarm ekskl skulderprotese m/bk 
224O Op på humerus/albue/underarm ekskl skulderprotese, dagkirugisk behandling 
224 Op på humerus/albue/underarm ekskl skulderprotese u/bk 
225O Operasjoner på ankel og fot, dagkirugisk behandling 
225 Operasjoner på ankel & fot 
226 Bløtdelsoperasjoner ITAD m/bk 
227O Bløtdelsoperasjoner ITAD, dagkirurgisk behandling 
227 Bløtdelsoperasjoner ITAD u/bk 
228O Større op på håndlegg/hånd/tommel, dagkirugisk behandling 
228 Op på håndledd/hånd/tommel m/bk eller leddprotese håndledd/hånd 
229O Op på håndledd/ hånd ekskl større leddop, dagkirurgisk behandling 
229 Op på håndledd/hånd u/bk eller sårrevisjon på overekstremitet 
233 Op på skjelett-muskelsystem og bindevev ITAD m/bk 
234O Op på skjelett-muskelsystem og bindevev ITAD, dagkirurgisk behandling 
234 Op på skjelett-muskelsystem og bindevev ITAD u/bk 
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Appendix 12 Population of Norway 
Region 
1. January 
2009 
1. January 
2010 
1. January 
2011 
1. January 
2012 
1. January 
2013 
South-Eastern Norway RHA 2 672 951 2 707 012 2 743 875 2 785 259 2 821 116 
Østfold 268 584 271 662 274 827 278 352 282 000 
Akershus 527 625 536 499 545 653 556 254 566 399 
Oslo 575 475 586 860 599 230 613 285 623 966 
Hedmark 190 071 190 709 191 622 192 791 193 719 
Oppland 184 288 185 216 186 087 187 147 187 254 
Buskerud 254 634 257 673 261 110 265 164 269 003 
Vestfold 229 134 231 286 233 705 236 424 238 748 
Telemark 167 548 168 231 169 185 170 023 170 902 
Aust-Agder 107 359 108 499 110 048 111 495 112 772 
Vest-Agder 168 233 170 377 172 408 174 324 176 353 
Western Norway RHA 996 712 1 012 202 1 028 069 1 041 886 1 058 994 
Rogaland 420 574 427 947 436 087 443 115 452 159 
Hordaland 469 681 477 175 484 240 490 570 498 135 
Sogn og Fjordane 106 457 107 080 107 742 108 201 108 700 
Central Norway RHA 666 164 673 364 680 110 687 968 696 602 
Møre og Romsdal 248 727 251 262 253 904 256 628 259 404 
Sør-Trøndelag 286 729 290 547 294 066 297 950 302 755 
Nord-Trøndelag 130 708 131 555 132 140 133 390 134 443 
Northern Norway RHA 463 425 465 621 468 251 470 757 474 563 
Nordland 235 380 236 271 237 280 238 320 239 611 
Troms  155 553 156 494 157 554 158 650 160 418 
Finnmark  72 492 72 856 73 417 73 787 74 534 
Norway 4 799 252 4 858 199 4 920 305 4 985 870 5 051 275 
Source: SSB 
 
 
Appendix 13 Population base for estimating costs per capita 
Year 
Western 
Norway RHA 
Central Norway 
RHA 
Northern 
Norway RHA 
South-Eastern 
Norway RHA 
Total 
2009 1 004 457 669 764 464 523 2 689 982 4 828 726 
2010 1 020 136 676 737 466 936 2 725 444 4 889 252 
2011 1 034 978 684 039 469 504 2 764 567 4 953 088 
2012 1 050 440 692 285 472 660 2 803 188 5 018 573 
Source: SSB 
Method: Population 2009 = (population per 1. January 2009 + population per 1. January 2010) / 2  
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Appendix 14 Number of patients per year and region 
Year  
Western 
Norway 
RHA 
Central 
Norway 
RHA 
Northern 
Norway 
RHA 
South-
Eastern 
Norway 
RHA 
Other Total 
2009 4 111 2 638 2 145 11 721 71 20 671 
2010 4 025 2 743 2 152 11 605 102 20 601 
2011 3 671 2 908 2 114 12 166 76 20 916 
2012 4 024 3 014 2 217 12 944 88 22 252 
Total           36 170 
 
 
Appendix 15 DRG unit price by year and type (Day care, in-hospital care and 
out-patient care) 
Year In-hospital care and day care Out-hospital care 
2009 35 127 1 066 
2010 35 964 35 964 
2011 36 968 36 968 
2012 38 209 38 209 
Source: (51-54) 
 
 
